Skip to main content
. Author manuscript; available in PMC: 2020 Apr 15.
Published in final edited form as: Clin Cancer Res. 2019 Jul 23;25(20):6160–6169. doi: 10.1158/1078-0432.CCR-18-3603

Table 3b.

Multivariable model for PFS and OS in patients who underwent genomic profiling (n=89)

PFS OS

HR (95% CI) p-value HR (95% CI) p-value
TMB (log-scale) 0.79 0.058 0.96 (0.7–1.3) 0.802

ECOG PS 1.74 (0.1–3.2) 0.075 2.35 (1.2–4.7) 0.015
≥2 vs. 0–1

No. of metastatic sites 1.66 (0.1–2.9) 0.078 2.71 (1.4–5.2) 0.002
≥3 vs. <3

No. of prior therapies NA NA 1.67 (0.9–3.0) 0.087
≥3 vs. <3

PS, performance status; No., number; ICI, immune checkpoint inhibitor; NA, not applicable (not significant in univariate analysis); TMB, tumor mutation burden. Significant values highlighted in bold.